Les informations fournies sur EL7.AI sont uniquement à des fins éducatives et informatives et ne constituent pas un conseil financier.
Les informations fournies sur EL7.AI sont uniquement à des fins éducatives et informatives et ne constituent pas un conseil financier.
On March 17, the National Comprehensive Cancer Network (NCCN) updated its 2026 Clinical Practice Guidelines to include ANKTIVA in combination with BCG, targeting patients with BCG-unresponsive non-muscle invasive bladder cancer. ImmunityBio, a commercial-stage immunotherapy company listed on NASDAQ, is behind this treatment. However, on March 24, ImmunityBio's shares fell 20% after the U.S. Food and Drug Administration issued a warning letter stating that a television advertisement and podcast promoting its cancer therapy were false or misleading and violated federal law.